Surgical Treatment of Juvenile Idiopathic Arthritis in the Era of Novel Drug Therapies.
Céline KleinVincent BarbierChristophe GlorionRichard GouronPublished in: Journal of clinical medicine (2023)
Juvenile idiopathic arthritis is the most common chronic rheumatic disease encountered in children under the age of sixteen and causes significant impairments in daily life. Over the last two decades, the introduction of new drug treatments (including disease-modifying antirheumatic drugs and biologics) has changed the course of this disease, thus reducing the indication for surgery. However, some patients fail to respond to drug therapy and thus require personalized surgical management, e.g., the local reduction of joint effusion or a synovial pannus (via intra-articular corticosteroid injections, synovectomy, or soft tissue release), and management of the sequelae of arthritis (such as growth disorders and joint degeneration). Here, we provide an overview of the surgical indications and outcomes of the following interventions: intra-articular corticosteroid injections, synovectomy, soft tissue release, surgery for growth disorders, and arthroplasty.
Keyphrases
- juvenile idiopathic arthritis
- soft tissue
- rheumatoid arthritis
- disease activity
- minimally invasive
- end stage renal disease
- coronary artery bypass
- physical activity
- chronic kidney disease
- drug induced
- newly diagnosed
- young adults
- ultrasound guided
- ejection fraction
- adverse drug
- rheumatoid arthritis patients
- systemic lupus erythematosus
- peritoneal dialysis
- metabolic syndrome
- bone marrow
- mesenchymal stem cells
- acute coronary syndrome
- patient reported outcomes